Skip to Content
Merck
All Photos(1)

Key Documents

SML3662

Sigma-Aldrich

Etrasimod arginine

≥98% (HPLC)

Synonym(s):

APD 334 L-Arginine, L-Arginine mono[(3R)-7-[[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy]-1,2,3,4-tetrahydrocyclopent[b]indol-3-yl]acetate, L-Arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C32H40F3N5O5
CAS Number:
Molecular Weight:
631.69
UNSPSC Code:
12352209
UNSPSC Code:
12352200
NACRES:
NA.25

Quality Level

Assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear (Warmed)

storage temp.

-10 to -25°C

SMILES string

N[C@@H](CCCNC(N)=N)C(O)=O.O=C(O)C[C@H]1CCC2=C1NC3=C2C=C(OCC4=CC=C(C5CCCC5)C(C(F)(F)F)=C4)C=C3

Biochem/physiol Actions

Etrasimod arginine is an orally available, potent, and selective agonist of Sphingosine-1-Phosphate Receptors 1 (S1PR1). Also, it acts as a partial agonist of S1PR4,5. Etrasimod arginine induces reductions in lymphocyte counts in mice. It is acting as immunosuppressive agents.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Hussien Al-Shamma et al.
The Journal of pharmacology and experimental therapeutics, 369(3), 311-317 (2019-03-16)
Lymphocyte trafficking out of secondary lymphoid organs is regulated by concentration gradient-dependent interactions between the membrane-derived lysophospholipid signaling molecule sphingosine 1-phosphate (S1P) and the G-protein-coupled receptor, S1P1 Etrasimod is a novel, next-generation, small-molecule, oral S1P receptor modulator in clinical development
Arianna Dal Buono et al.
Biomedicines, 10(7) (2022-07-28)
Inflammatory bowel diseases (IBDs) are chronic and disabling conditions that, uncontrolled, lead to irreversible bowel damage and associated comorbidities. Despite the new era of biological therapies, IBDs remain not curative. The treatment purpose is to induce endoscopic remission, reduce the
Matej Zore et al.
Frontiers in microbiology, 13, 926170-926170 (2022-06-24)
New classes of antibiotics are urgently needed in the fight against multidrug-resistant bacteria. Drug repurposing has emerged as an alternative approach to accelerate antimicrobial research and development. In this study, we screened a library of sphingosine-1-phosphate receptor (S1PR) modulators against

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service